FDAsafety guidance66% confidence
FDA AP — BAXFENDY (ORIG)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for AstraZeneca; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application NDA219878. Sponsor: ASTRAZENECA AB. Submission status: AP. Submission type: ORIG. Review priority: PRIORITY. Active ingredients: BAXDROSTAT.
Supporting Context
- Therapeutic area
- Oncology · AKT Inhibitor
- Sub-indication
- General
Related signal: FDA Acceptance of NDA for Capivasertib by AstraZeneca